$HCTI 💡+ Blockchain = Trust Infrastructure for Healthcare
Healthcare is moving fast toward verifiable, auditable, secure data exchange, and blockchain isn’t a buzzword anymore — it’s becoming infrastructure. (See the LinkedIn thread on blockchain securing healthcare 🧠🔗)
Here’s why $HCTI is perfectly positioned:
🚀 Secure Data Pipelines Meet Blockchain Principles
• tamper-proof audit trails
• identity + consent management
• verified record provenance
• seamless interoperability across EHR + cloud systems
🏥 Hospitals spend more during economic pressure on systems that reduce risk, improve compliance, and unlock AI safely. That’s HCTI’s lane.
📈 Healthcare’s “trust tech” wave is coming, and $HCTI sits at the intersection of AI + cloud + secure data architecture.
Compare to moves in:
🔹 $MDRX (EHR interoperability)
🔹 $ONEM (care-delivery data integration)
🔹 $VRTX (advanced biotech & digital infrastructure alignment)
HCTI looks early. Undervalued.
Stopped out of $RDDT for the last time. I've had several IPOs over the years that just took my money and it took me a few times to ban them from watchlist. $ONEM was one of those a few years ago that spun me around a bunch. See ya $RDDT.
@FSRmoonster I think if they go through with it (and henrik gets an offer that can allow him to feel successful - pride always being an issue with him), then this is the dilligence period he spoke of. @dbrownst is really the only person qualified to answer this, but I know with saint archer and Landon’s subsequent ventures the investors walked with a healthy portion. The funniest thing here about the bears is Stock would halt before the deal is finalized and they’d have to close at the agreed price. I’ve been through a bunch of then because this is the exact play I look for in the market - last one I nailed was $ONEM getting bought by Amazon. TLDR answer sorry, but here’s an educated guess: we know the FSR deSPAC $10 was 2.9B NAV. Since then let’s say we’ve had 100 percent dilution (not exactly out of question unfortunately) hell let’s say we’re at triple dilution. So that book value would now be 9B at 10$ ps. 20b, $18 ps? On the other hand. I’ve had one beer so this be brewskimath
$DCGO
DCGO Q3’23 Key Notes
✅ Strong revenue growth at 49% YoY, even stronger with ex-Covid testing at 70% YoY
✅ Guided $505M to start the year and now will most likely finish at $620M for total year revenue, showing incredible demand and need for services/products, despite higher interest rate environment
✅ Operating margin expansion; adjusted EBITDA grew 84% faster than 49% revenue growth for Q3
✅ Strong management and efficient use of marketing and capital, as SG&A is not expected to reach past 10% of revenue going forward
✅ $105M or 32% increase in backlog to $430M from $325M in 1 quarter, providing strong visibility into 2024 growth
Still a low multiple compared to peers in $TDOC $ONEM
$TDOC illogical for $ONEM to fly 8.55% if u look at Mkt Cap 3.4B and EPS -2.02. TDOC has full suites products offering in 100 countries and capability over 20 years and supported by 4K staff is flying under radar ! Sthg missing . Your thoughts .
